Tissue Regenix Group plc TSSNF OTC

Tissue Regenix Group plc (TSSNF) has shown exceptional revenue growth over the past 3 years, expanding from $14M to $29M (average +28%/yr). The company reported a net loss of $713,000 in its most recent fiscal year, with earnings trending at 39.1%/yr. The net profit margin is -2.5%, which is negative. The company has not reported a profit in any of the last 4 years tracked. The gross margin is 47.5% (moderate), with a +8.3pp trend over the period. With a market cap data available and MOAT composite score of 43/100, the company has a low competitive position.

Criteria proven by this page:

• GROWTH (100/100, Pass) — proving strong growth momentum
• PAST (0/100, Fail) — the company has frequently reported losses. Looking at the full 18-year history, the company was profitable in 0 of 18 years — a mixed long-term record
• INCOME (10/100, Fail) — the company is currently operating at a loss
• MOAT (43/100, Fail) — limited competitive moat based on margins and scale

Overall SharesGrow Score: 44/100 with 1/5 criteria passed.